Insights into the distinguishing stress-induced cytotoxicity of Chiral gold nanoclusters and the relationship with GSTP1

Theranostics

Volumn 5, Issue 2, 2015, Pages 134-149

  Zhang, Chunlei ^a   Zhou, Zhijun ^a   Zhi, Xiao ^a   Ma, Yue ^a   Wang, Kan ^a   Wang, Yuxia ^b   Zhang, Yingge ^b   Fu, Hualin ^a   Jin, Weilin ^a   Pan, Fei ^a   Cui, Daxiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Chirality; Cytotoxicity; Epigenetic analysis; Gold nanocluster; Methylation; Ros

Indexed keywords

CHIRAL GOLD NANOCLUSTER; GLUTATHIONE; GLUTATHIONE TRANSFERASE P1; GOLD NANOPARTICLE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; CYTOTOXIN; GOLD; GSTP1 PROTEIN, HUMAN; NANOPARTICLE;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CYCLE ARREST; CELL VIABILITY; CELLULAR STRESS RESPONSE; CHIRALITY; CIRCULAR DICHROISM; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; DNA MICROARRAY; DRUG CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MEMBRANE DEPOLARIZATION; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PHOTOLUMINESCENCE; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY; UPREGULATION; CELL CYCLE; CELL LINE; DRUG EFFECTS; GENE EXPRESSION PROFILING;

APOPTOSIS; CELL CYCLE; CELL LINE; CYTOTOXINS; GENE EXPRESSION PROFILING; GLUTATHIONE S-TRANSFERASE PI; GOLD; HUMANS; NANOPARTICLES; REACTIVE OXYGEN SPECIES;

EID: 84923221650     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10363     Document Type: Article

References (46)

1. Blackmond DG. The origin of biological homochirality. Cold Spring Harbor perspectives in biology. 2010; 2: a002147.
2. Amabilino D. Chirality at the Nanoscale: Nanoparticles, surfaces, materials and more. Germany: Wiley-VCH Weinheim Publisher; 2009.
3. Farrag M, Tschurl M, Heiz U. Chiral gold and silver nanoclusters: Preparation, size selection, and chiroptical properties. Chem Mater. 2013; 25: 862-70.
4. Slocik JM, Govorov AO, Naik RR. Plasmonic circular dichroism of peptide-functionalized gold nanoparticles. Nano lett. 2011; 11: 701-5.
5. 25 nanospheres and nanorods: synthesis and insight into the origin of chirality. Nano lett. 2011; 11: 3963-9.
6. Zhang C, Zhou Z, Qian Q, Gao G, Li C, Feng L, et al. Glutathione-capped fluorescent gold nanoclusters for dual-modal fluorescence/X-ray computed tomography imaging. J Mater Chem B. 2013; 1: 5045-53.
7. Qian H, Zhu M, Wu Z, Jin R. Quantum sized gold nanoclusters with atomic precision. Acc Chem Res. 2012; 45: 1470-9.
8. Xu Q, Kumar S, Jin S, Qian H, Zhu M, Jin R. Chiral 38-Gold-Atom Nanoclusters: Synthesis and Chiroptical Properties. Small. 2013.
9. Knoppe S, Bürgi T. Chirality in Thiolate-Protected Gold Clusters. Acc Chem Res. 2014; 47: 1318-26.
10. Schaaff TG, Knight G, Shafigullin MN, Borkman RF, Whetten RL. Isolation and selected properties of a 10.4 kDa gold: glutathione cluster compound. J Phys Chem B. 1998; 102: 10643-6.
11. Yao H, Fukui T, Kimura K. Chiroptical responses of D-/L-penicillamine-capped gold clusters under perturbations of temperature change and phase transfer. J Phys Chem C. 2007; 111: 14968-76.
12. Wu G, Fang Y-Z, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004; 134: 489-92.
13. Knoppe S, Dolamic I, Burgi T. Racemization of a chiral nanoparticle evidences the flexibility of the gold-thiolate interface. J Am Chem Soc. 2012; 134: 13114-20.
14. Dolamic I, Knoppe S, Dass A, Bürgi T. First enantioseparation and circular dichroism spectra of Au38 clusters protected by achiral ligands. Nat Commun. 2012; 3: 798-804.
15. Wang Y, Chen J, Irudayaraj J. Nuclear targeting dynamics of gold nanoclusters for enhanced therapy of HER2+ breast cancer. ACS nano. 2011; 5: 9718-25.
16. Liu J, Yu M, Zhou C, Yang S, Ning X, Zheng J. Passive tumor targeting of renal-clearable luminescent gold nanoparticles: long tumor retention and fast normal tissue clearance. J Am Chem Soc. 2013; 135: 4978-81.
17. 10-12 Nanomolecules for High Tumor Specificity and Cancer Radiotherapy. Adv Mater. 2014; 26: 4565-8.
18. Zhang X-D, Chen J, Luo Z, Wu D, Shen X, Song S-S, et al. Enhanced Tumor Accumulation of Sub-2 nm Gold Nanoclusters for Cancer Radiation Therapy. Adv Healthc Mater. 2014; 3: 133-41.
19. Li Y, Zhou Y, Wang HY, Perrett S, Zhao Y, Tang Z, et al. Chirality of glutathione surface coating affects the cytotoxicity of quantum dots. Angew Chem Int Ed. 2011; 50: 5860-4.
20. LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2', 7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol. 1992; 5: 227-31.
21. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta. 2003; 333: 19-39.
22. Pan Y, Leifert A, Ruau D, Neuss S, Bornemann J, Schmid G, et al. Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. Small. 2009; 5: 2067-76.
23. Ly J, Grubb D, Lawen A. The mitochondrial membrane potential (δψm) in apoptosis; an update. Apoptosis. 2003; 8: 115-28.
24. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med. 2000; 6: 513-9.
25. Karna P, Zughaier S, Pannu V, Simmons R, Narayan S, Aneja R. Induction of reactive oxygen species-mediated autophagy by a novel microtubule-modulating agent. J Biol Chem. 2010; 285: 18737-48.
26. Mah L, El-Osta A, Karagiannis T. γH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010; 24: 679-86.
27. AshaRani P, Low Kah Mun G, Hande MP, Valiyaveettil S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS nano. 2008; 3: 279-90.
28. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000; 404: 42-9.
29. Fan LM, Li J-M. Evaluation of methods of detecting cell reactive oxygen species production for drug screening and cell cycle studies. J Pharmacol Toxicol Methods. 2014; 70: 40-7.
30. Zhou YB, Feng X, Wang LN, Du JQ, Zhou YY, Yu HP, et al. LGH00031, a novel ortho-quinonoid inhibitor of cell division cycle 25B, inhibits human cancer cells via ROS generation. Acta Pharmacol Sin. 2009; 30: 1359-68.
31. Pillai S, Behra R, Nestler H, Suter MJ-F, Sigg L, Schirmer K. Linking toxicity and adaptive responses across the transcriptome, proteome, and phenotype of Chlamydomonas reinhardtii exposed to silver. Proc Natl Acad Sci. 2014; 111: 3490-5.
32. Xie Y, Lai D, Mao Y, Zhang W, Shen W, Guan R. Molecular cloning, characterization, and expression analysis of a novel gene encoding L-cysteine desulfhydrase from Brassica napus. Mol Biotechnol. 2013; 54: 737-46.
33. Diwakar L, Ravindranath V. Inhibition of cystathionine-gamma-lyase leads to loss of glutathione and aggravation of mitochondrial dysfunction mediated by excitatory amino acid in the CNS. Neurochem Int. 2007; 50: 418-26.
34. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol. 2007; 47: 263-92.
35. Chatterjee N, Eom HJ, Choi J. A systems toxicology approach to the surface functionality control of graphene-cell interactions. Biomaterials. 2014; 35: 1109-27.
36. Li X, He Q, Shi J. Global gene expression analysis of cellular death mechanisms induced by mesoporous silica nanoparticle-based drug delivery system. ACS Nano. 2014; 8: 1309-20.
37. Gou N, Onnis-Hayden A, Gu AZ. Mechanistic toxicity assessment of nanomaterials by whole-cell-array stress genes expression analysis. Environ Sci Technol. 2010; 44: 5964-70.
38. Eichten SR, Schmitz RJ, Springer N. Epigenetics: more than chromatin modifications and complex gene regulatory systems. Plant Physiol. 2014.
39. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science. 2001; 293: 1068-70.
40. Ronneberg JA, Tost J, Solvang HK, Alnaes GI, Johansen FE, Brendeford EM, et al. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Res. 2008; 68: 5562-71.
41. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002; 21: 5400-13.
42. Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res. 2001; 7: 2727-30.
43. Hayes JD, Strange RC. Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. Free Radic Res. 1995; 22: 193-207.
44. Kumar V, Yadav CS, Datta SK, Singh S, Ahmed RS, Goel S, et al. Association of GSTM1 and GSTT1 polymorphism with lipid peroxidation in benign prostate hyperplasia and prostate cancer: a pilot study. Dis Markers. 2011; 30: 163-9.
45. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002; 21: 5483-95.
46. Prifti E, Zucker J-D, Clement K, Henegar C. FunNet: an integrative tool for exploring transcriptional interactions. Bioinformatics. 2008; 24: 2636-8.